A Randomized Controlled Trial of Wellbutrin for Crohn's Disease
Wellbutrin (bupropion) is approved for use as an antidepressant. There have been some cases
in which people on Wellbutrin had significant improvement clinically in their Crohn's
disease. In this trial, the hypothesis that Wellbutrin can induce clinical remission in
Crohn's disease will be tested. The investigators will also be looking to see if Wellbutrin
can lower levels of the inflammatory cytokine tumor necrosis factor-alpha (TNF).
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Number of patients with Crohn's disease activity index (CDAI) < 150 at the end of twelve weeks
0, 2, 4, 8, 12 weeks
Eric L Altschuler, M.D., Ph.D.
Mt. Sinai Medical Center
United States: Food and Drug Administration
|University of Chicago||Chicago, Illinois 60637|
|Mt. Sinai Medical Center||New York, New York 10029|